FLT3 programme licensing opportunity
Sentinel Oncology is pleased to announce that its FLT3 kinase programme is available for partnering.
Mutations in the FLT3 gene are amongst the most frequent genetic defects found in acute myeloid leukemia (AML). Sentinel Oncology has developed a novel lead series of small molecule drugs which act as potent inhibitors of FLT3 and represent an excellent opportunity to develop pre-clinical candidate drugs... read more
For more information about the Sentinel Oncology p70S6 kinase programme, visit our website at www.sentineloncology.com or contact us to arrange a collaborative discussion.
March 30, 2010
Events
Sentinel Oncology will be participating in the following events
15th April 2010
Anglo Nordic Biotech conference
London, UK
3rd-6th May 2010
BIO International Convention
Chicago, IL, USA
4th-8th June 2010
ASCO
Chicago, IL, USA
10th-12th October 2010
BPE
London, UK
9th December 2010
Genesis conference
London, UK